Parexel China Co.,Ltd.

Primary objectives: To evaluate the PK of 50 IU/kg rIX-FP in previously treated Chinese patients with hemophilia B (FIX activity ≤2%) in the single-dose PK phase; to evaluate the efficacy of routine prophylactic administration of rIX-FP in preventing spontaneous bleeding events in previously treated Chinese patients with hemophilia B (FIX activity ≤2%); to evaluate the safety of routine prophylactic administration of rIX-FP in the formation of FIX inhibitors in previously treated Chinese patients with hemophilia B (FIX activity ≤2%).

The primary objective of this study is to evaluate the efficacy and safety of Oxervate® for the treatment of moderate or severe neurotrophic keratitis (NK) in real-world clinical practice. The proposed efficacy evaluations are: 1. Complete healing of moderate (persistent corneal epithelial defect) or severe (corneal ulcer) neurotrophic keratitis (NK) assessed by the investigator using corneal fluorescein staining (using the Oxford scale) 2. Durability of complete healing during follow-up 3. Improvement of corneal perception The secondary objectives of this study are to gain a deeper understanding of the use of this topical treatment in real-world clinical practice and to evaluate the pharmacokinetic characteristics and systemic exposure of Oxervate® in the Chinese population

Objective: To evaluate the pharmacokinetic characteristics, safety, and tolerability of safinamide after single and multiple doses in healthy Chinese adult volunteers.